이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Heidelberg Pharma 대차 대조표 상태

재무 상태 기준 확인 3/6

Heidelberg Pharma 의 총 주주 지분은 €45.1M 이고 총 부채는 €5.1M, 이는 부채 대 자기자본 비율을 11.2% 로 가져옵니다. 총자산과 총부채는 각각 €61.7M 및 €16.6M 입니다.

주요 정보

11.2%

부채 비율

€5.07m

부채

이자 보상 비율	n/a
현금	€32.65m
주식	€45.11m
총 부채	€16.55m
총 자산	€61.67m

최근 재무 상태 업데이트

Recent updates

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Feb 16

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Dec 05

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Jul 21

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Oct 16

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Nov 28

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Mar 27

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Mar 15

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Jan 17

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Dec 14

재무 상태 분석

단기부채: HPHA 의 단기 자산 ( €48.1M )이 단기 부채( €16.5M ).

장기 부채: HPHA 의 단기 자산( €48.1M )이 장기 부채( €69.8K ).

부채 대 자본 내역 및 분석

부채 수준: HPHA 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: HPHA 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 11.2% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: HPHA 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 19.8 %의 역사적 비율로 계속 감소할 경우 HPHA 의 현금 활주로는 1년 미만입니다.

Heidelberg Pharma 대차 대조표 상태

재무 상태 기준 확인 3/6

주요 정보

최근 재무 상태 업데이트

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Recent updates

New major risk - Financial position

First quarter 2024 earnings released: €0.10 loss per share (vs €0.14 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 33% to €8.90

Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?

Heidelberg Pharma AG to Report First Half, 2024 Results on Jul 11, 2024

Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues

Price target decreased by 24% to €6.70

Third quarter 2023 earnings released: EPS: €0.002 (vs €0.14 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%

Consensus revenue estimates increase by 21%

Second quarter 2023 earnings released

Heidelberg Pharma Ag Announces Executive Changes

Price target decreased by 19% to €8.87

Consensus revenue estimates fall by 60%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to €10.30

Consensus forecasts updated

Consensus revenue estimates increase by 83%

Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher

Third quarter 2022 earnings released: €0.14 loss per share (vs €0.17 loss in 3Q 2021)

Second quarter 2022 earnings released: €0.04 loss per share (vs €0.22 loss in 2Q 2021)

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2022

Consensus revenue estimates increase by 87%

First quarter 2022 earnings: EPS misses analyst expectations

Price target increased to €10.78

Heidelberg Pharma AG announced that it expects to receive €36 million in funding

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma

Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: €0.17 loss per share (vs €0.096 loss in 3Q 2020)

Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 in the US

CEO, CFO & Member of the Executive Management Board Jan Schmidt-Brand has left the company

Heidelberg Pharma AG Provides Financial Guidance for 2021

Forecast to breakeven in 2023

Second quarter 2021 earnings released: €0.22 loss per share (vs €0.17 loss in 2Q 2020)

Heidelberg Pharma to Present Its Proprietary ATAC Technology

Consensus revenue estimates fall to €7.56m

First quarter 2021 earnings released: €0.20 loss per share (vs €0.16 loss in 1Q 2020)

Heidelberg Pharma AG Reaffirms Earnings Guidance for 2021

Full year 2020 earnings released: €0.61 loss per share (vs €0.36 loss in FY 2019)

Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be

Heidelberg Pharma AG Provides Earnings Guidance for the Year 2021

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

Heidelberg Pharma AG Heidelberg Pharma Expands Management Team

New 90-day high: €7.68

Heidelberg Pharma AG and Indiana University Publish Results on HER2-ATAC for Targeted Immunotherapy of Triple Negative Breast Cancer in Science Translational Medicine

Price target raised to €6.52

Heidelberg Pharma AG Announces FDA Allows the Company to Start A Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%

Heidelberg Pharma AG, Annual General Meeting, May 18, 2021

We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully

New 90-day high: €5.94

New 90-day high: €4.90

Heidelberg Pharma AG Announces Several Presentations of Research Results on ATAC Technology At the ASH Annual Meeting 2020

Analysts update estimates

New 90-day low: €3.69

Heidelberg Pharma AG Updates Financial Guidance for the Year 2020

Third quarter earnings released

New 90-day low: €3.91

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기